Selling Stem Cells
Californians are set to vote on a proposal to spend $300 million a year over the next 10 years for stem cell research. For some perspective on how big a deal this would be, the federal government spent $25 million last year. The ballot measure, known as Proposition 71, is being financially supported by a strong cadre of entertainers, business people, and others, including Nancy Reagan, as the New York Times reports today and would be a strong counteraction to the Bush administration’s ban on new stem cell lines. But is the Times overstating the number of potential beneficiaries of stem cell research? The paper writes, “half of California’s families are affected by one or more of the 70 diseases or conditions that could respond to stem cell therapies,” in which they include Alzheimer’s disease. (Approximately 500,000 Californians have Alzheimer’s disease.) But as the Washington Post reported in June, stem cells are an unlikely therapy for Alzheimers, which involves the loss of huge numbers and varieties of the brain’s 100 billion nerve cells. Lest California voters come to wonder just what they’ve been sold, it may be better to be up front about it in the first place.
Keep Reading
Most Popular
DeepMind’s cofounder: Generative AI is just a phase. What’s next is interactive AI.
“This is a profound moment in the history of technology,” says Mustafa Suleyman.
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
Human-plus-AI solutions mitigate security threats
With the right human oversight, emerging technologies like artificial intelligence can help keep business and customer data secure
Next slide, please: A brief history of the corporate presentation
From million-dollar slide shows to Steve Jobs’s introduction of the iPhone, a bit of show business never hurt plain old business.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.